# Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction

> **NCT07467213** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Samsung Medical Center** · enrollment: 5000 (estimated)

## Conditions studied

- Acute Myocardial Infarction (AMI)
- Gastrointestinal Bleeding

## Interventions

- **DRUG:** Zastaprazan
- **DRUG:** Proton Pump Inhibitors (PPI)

## Key facts

- **NCT ID:** NCT07467213
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 5000 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07467213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07467213, "Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07467213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*